Genas’ Michaela Palagyi shares the association’s pride in being an affiliate member of Medicines for Europe and how this allows them to liaise more closely with their European counterparts. She also reveals the share of generics in today’s Slovak pharma market: around 60 per cent of volume and slightly less than 50 per cent of overall market value.
Could you please start by introducing the purpose, capabilities and scope of offering of the Generics Manufacturers Association of Slovakia (GENAS)?
Having an organization in place like GENAS enables our members to forge a common understanding of the national legislation and to speak with a single, united voice when engaging with the authorities, the media and any other stakeholders.
